Endocannabinoid System Targeted Therapeutics Market

Table Of Content

Executive Summary
1. Introduction
Market Introduction
1. Market Definition
2. Scope of the Study
3. Market Structure
Research Methodology
1. Primary Research
2. Research Methodology
3. Assumptions & Exclusions
4. Secondary Data Sources
Market Factor Analysis
1. Value Chain Analysis: Endocannabinoid System Targeted Therapeutics Market
2. Porters Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of Substitution
  4. Threat of New Entrants
  5. Competitive Rivalry
Market Dynamics
1. Drivers
2. Restraints
3. Opportunities
Recent Trends Analysis
Impact of COVID-19 on Endocannabinoid System Targeted Therapeutics Market
1. Pre and Post Covid -19 Market Scenario Analysis
2. Market Recovery Timeline and Challenge
3. Measures Taken by Top Players
Regulatory Landscape
Endocannabinoid System Targeted Therapeutics Market, By Therapeutic Applications
1. Introduction
  1. Market Size and Forecast, By Therapeutic Applications
2. Neurological Disorders
  1. Market Size and Forecast, By Region
3. Chronic Pain
  1. Market Size and Forecast, By Region
4. Inflammatory Diseases
  1. Market Size and Forecast, By Region
5. Psychiatric Conditions
  1. Market Size and Forecast, By Region
6. By Drug Types
  1. Market Size and Forecast, By Region
7. Synthetic Cannabinoids
  1. Market Size and Forecast, By Region
8. Phytocannabinoids
  1. Market Size and Forecast, By Region
9. Endocannabinoid Modulators
  1. Market Size and Forecast, By Region
Endocannabinoid System Targeted Therapeutics Market, By Routes Of Administration
1. Introduction
  1. Market Size and Forecast, By Routes Of Administration
2. Oral
  1. Market Size and Forecast, By Region
3. Inhalation
  1. Market Size and Forecast, By Region
4. Topical
  1. Market Size and Forecast, By Region
5. Sublingual
  1. Market Size and Forecast, By Region
6. By End-Users
  1. Market Size and Forecast, By Region
7. Hospitals
  1. Market Size and Forecast, By Region
8. Clinics
  1. Market Size and Forecast, By Region
9. Research Institutes
  1. Market Size and Forecast, By Region
Regional Overview
1. Introduction
  1. Market Size and Forecast
2. North America
  1. Market Size and Forecast
    1. By Therapeutic Applications
      1. Neurological Disorders
      2. Chronic Pain
      3. Inflammatory Diseases
      4. Psychiatric Conditions
      5. By Drug Types
      6. Synthetic Cannabinoids
      7. Phytocannabinoids
      8. Endocannabinoid Modulators
    2. By Routes Of Administration
      1. Oral
      2. Inhalation
      3. Topical
      4. Sublingual
      5. By End-Users
      6. Hospitals
      7. Clinics
      8. Research Institutes
  2. U.S.
    1. By Therapeutic Applications
      1. Neurological Disorders
      2. Chronic Pain
      3. Inflammatory Diseases
      4. Psychiatric Conditions
      5. By Drug Types
      6. Synthetic Cannabinoids
      7. Phytocannabinoids
      8. Endocannabinoid Modulators
    2. By Routes Of Administration
      1. Oral
      2. Inhalation
      3. Topical
      4. Sublingual
      5. By End-Users
      6. Hospitals
      7. Clinics
      8. Research Institutes
  3. Canada
3. Europe
  1. Market Size and Forecast
    1. By Therapeutic Applications
      1. Neurological Disorders
      2. Chronic Pain
      3. Inflammatory Diseases
      4. Psychiatric Conditions
      5. By Drug Types
      6. Synthetic Cannabinoids
      7. Phytocannabinoids
      8. Endocannabinoid Modulators
    2. By Routes Of Administration
      1. Oral
      2. Inhalation
      3. Topical
      4. Sublingual
      5. By End-Users
      6. Hospitals
      7. Clinics
      8. Research Institutes
  2. U.K.
    1. By Therapeutic Applications
      1. Neurological Disorders
      2. Chronic Pain
      3. Inflammatory Diseases
      4. Psychiatric Conditions
      5. By Drug Types
      6. Synthetic Cannabinoids
      7. Phytocannabinoids
      8. Endocannabinoid Modulators
    2. By Routes Of Administration
      1. Oral
      2. Inhalation
      3. Topical
      4. Sublingual
      5. By End-Users
      6. Hospitals
      7. Clinics
      8. Research Institutes
  3. Germany
  4. France
  5. Spain
  6. Italy
  7. Russia
  8. Nordic
  9. Benelux
  10. Rest of Europe
4. APAC
  1. Market Size and Forecast
    1. By Therapeutic Applications
      1. Neurological Disorders
      2. Chronic Pain
      3. Inflammatory Diseases
      4. Psychiatric Conditions
      5. By Drug Types
      6. Synthetic Cannabinoids
      7. Phytocannabinoids
      8. Endocannabinoid Modulators
    2. By Routes Of Administration
      1. Oral
      2. Inhalation
      3. Topical
      4. Sublingual
      5. By End-Users
      6. Hospitals
      7. Clinics
      8. Research Institutes
  2. China
    1. By Therapeutic Applications
      1. Neurological Disorders
      2. Chronic Pain
      3. Inflammatory Diseases
      4. Psychiatric Conditions
      5. By Drug Types
      6. Synthetic Cannabinoids
      7. Phytocannabinoids
      8. Endocannabinoid Modulators
    2. By Routes Of Administration
      1. Oral
      2. Inhalation
      3. Topical
      4. Sublingual
      5. By End-Users
      6. Hospitals
      7. Clinics
      8. Research Institutes
  3. Korea
  4. Japan
  5. India
  6. Australia
  7. Singapore
  8. Taiwan
  9. South East Asia
  10. Rest of Asia-Pacific
5. Middle East and Africa
  1. Market Size and Forecast
    1. By Therapeutic Applications
      1. Neurological Disorders
      2. Chronic Pain
      3. Inflammatory Diseases
      4. Psychiatric Conditions
      5. By Drug Types
      6. Synthetic Cannabinoids
      7. Phytocannabinoids
      8. Endocannabinoid Modulators
    2. By Routes Of Administration
      1. Oral
      2. Inhalation
      3. Topical
      4. Sublingual
      5. By End-Users
      6. Hospitals
      7. Clinics
      8. Research Institutes
  2. UAE
    1. By Therapeutic Applications
      1. Neurological Disorders
      2. Chronic Pain
      3. Inflammatory Diseases
      4. Psychiatric Conditions
      5. By Drug Types
      6. Synthetic Cannabinoids
      7. Phytocannabinoids
      8. Endocannabinoid Modulators
    2. By Routes Of Administration
      1. Oral
      2. Inhalation
      3. Topical
      4. Sublingual
      5. By End-Users
      6. Hospitals
      7. Clinics
      8. Research Institutes
  3. Turky
  4. Saudi Arabia
  5. South Africa
  6. Egypt
  7. Nigeria
  8. Rest of MEA
6. LATAM
  1. Market Size and Forecast
    1. By Therapeutic Applications
      1. Neurological Disorders
      2. Chronic Pain
      3. Inflammatory Diseases
      4. Psychiatric Conditions
      5. By Drug Types
      6. Synthetic Cannabinoids
      7. Phytocannabinoids
      8. Endocannabinoid Modulators
    2. By Routes Of Administration
      1. Oral
      2. Inhalation
      3. Topical
      4. Sublingual
      5. By End-Users
      6. Hospitals
      7. Clinics
      8. Research Institutes
  2. Brazil
    1. By Therapeutic Applications
      1. Neurological Disorders
      2. Chronic Pain
      3. Inflammatory Diseases
      4. Psychiatric Conditions
      5. By Drug Types
      6. Synthetic Cannabinoids
      7. Phytocannabinoids
      8. Endocannabinoid Modulators
    2. By Routes Of Administration
      1. Oral
      2. Inhalation
      3. Topical
      4. Sublingual
      5. By End-Users
      6. Hospitals
      7. Clinics
      8. Research Institutes
  3. Mexico
  4. Argentina
  5. Chile
  6. Colombia
  7. Rest of LATAM
Competitive Landscape, 2024
1. Introduction
2. Endocannabinoid System Targeted Therapeutics Market Share Analysis, 2024 (%)
  1. Market Share Analysis, 2024
  2. Competition Ranking, 2024
  3. Key Developments & Growth Strategies
    1. Merger & Acquisition
    2. Product Launch
    3. Expansion
  4. Consolidated SWOT Analysis of Key Players
Company Profile
1. GW Pharmaceuticals
  1. Business Overview
  2. Financial Data
  3. Key Product Categories
  4. Recent Developments
2. Jazz Pharmaceuticals
3. Tilray Inc.
4. Canopy Growth Corporation
5. Aurora Cannabis
6. Charlotte's Web Holdings
7. Cronos Group Inc.
8. Zoetic International
9. Corbus Pharmaceuticals
10. MediPharm Labs
11. Emerald Health Pharmaceuticals
12. Quolet
13. Zynerba Pharmaceuticals
14. Aphria Inc.
15. Vivo Cannabis Inc.

	


A PHP Error was encountered

Severity: Warning
Message:  Undefined array key "list_tbl_fig"
Filename: reports/toc.php
Line Number: 79


	Backtrace:
	
		
	
		
	
		
			
			File: /var/www/html/application/views/frontend/reports/toc.php

			Line: 79

			Function: _error_handler			

		
	
		
	
		
	
		
			
			File: /var/www/html/application/controllers/Web.php

			Line: 215

			Function: view			

		
	
		
	
		
			
			File: /var/www/html/index.php

			Line: 316

			Function: require_once

Check Discount

Get Free Sample

Buy Now

Key Topics Covered

Market Factors (Including Drivers and Restraint)
Market Trends
Market Estimates and Forcasts
Competitive Analysis
Future Market Opportunities

Endocannabinoid System Targeted Therapeutics Market By Type (Oral, Inhalation, Others), By Application (Autoimmune Disorders, Genetic Disorders, Neurological Disorders, Pain Disorders), Regional Analy. . . . .

Table Of Content

A PHP Error was encountered